MedPage Today -- SAN FRANCISCO, June 2 -- Some hepatitis C patients who don’t respond to standard therapy may get a second chance at eradication with daily interferon alfacon-1 (Infergen) plus ribavirin.
MedPage Today -- SAN FRANCISCO, June 2 -- Some hepatitis C patients who don’t respond to standard therapy may get a second chance at eradication with daily interferon alfacon-1 (Infergen) plus ribavirin.
